Navigation Links
Breast Cancer Patients May Have a New Treatment Option When Cancer Spreads
Date:2/22/2009

New procedure could offer a safer, more convenient treatment for spine tumors

LAS VEGAS, Feb. 22 /PRNewswire-USNewswire/ -- For orthopaedic researcher Joyce Keyak, Ph.D., finding ways to battle breast cancer is a personal as well as a professional mission. Her cousin died from the disease several years ago. Dr. Keyak still remembers the incredible pain her cousin experienced when the cancer spread to her spine. A new study released by Dr. Keyak and her colleagues at the University of California, Irvine, shows patients whose breast cancer metastasizes to their spines may have a better option than the usual treatment, which can include up to 10 sessions of radiation therapy. The study looked at alternative -- injecting radioactive bone cement into the vertebral body -- with promising results.

The UCI researchers collaborated with a colleague from St. Jude Heritage Medical Group in Fullerton, Calif., to investigate this technique. Dr. Keyak is presenting the team's findings in the paper "Feasibility of Using Radioactive Bone Cement to Treat Vertebral Metastases" during the 55th Annual Meeting of the Orthopaedic Research Society, Feb. 22-25, 2009, in Las Vegas.

"With further development, this technology may yield a clinically feasible procedure that would eliminate the need for 10 radiation therapy sessions, making it more convenient for the patient," says Dr. Keyak, an associate professor in UCI's department of orthopaedic surgery. "This procedure would also deliver a higher dose to the bone metastases and a lower dose to the spinal cord and other normal tissues than conventional external beam radiation therapy, potentially improving the clinical outcome," she explains. "The negligible dose to the spinal cord would also make it possible to treat recurrent spinal tumors in patients who have already received the maximum allowable radiation dose to the spinal cord."

According to the American Cancer Society, almost 185,000 people in the United States -- mainly women -- were diagnosed with invasive breast cancer in 2008. In addition, a study published in the journal Spine showed that, of those patients whose breast cancer metastasizes, almost 75 percent develop spine tumors.

Spinal metastases can cause pain and vertebral collapse. And, due to the proximity of the spinal cord and nerves, those tumors can lead to serious neurological complications. Conventional treatment often occurs in two phases:

  1. A surgical procedure (vertebroplasty or kyphoplasty) in which bone cement is injected into the body to stabilize the bone
  2. Subsequent external beam radiation therapy (or EBRT) to control tumor growth

The effectiveness of EBRT for spinal metastases is limited because the spinal cord restricts the dose of radiation that can be safely delivered. In addition, EBRT is typically provided in multiple sessions to reduce toxicity to the spinal cord, making treatment inconvenient for the patient.

The therapy investigated by Dr. Keyak and her colleagues would combine the two treatment phases into one procedure by mixing a radioactive compound with the injected cement. A single procedure using this radioactive bone cement would provide structural reinforcement to the bone while simultaneously irradiating the tumor from within (i.e., vertebral brachytherapy). Results of the study showed that a therapeutic dose of radiation would reach the intended bone without undue risk to tissue beyond a certain range (such as the spinal cord).

Once the results are validated, subsequent studies will look at the following:

  • Refining the choice of radioisotope(s), amount of activity and geographic distribution of the cement
  • Sensitivity of the radiation dose distribution to variations in bone size, density and tumor type; differences in bone cement formulations; and other factors associated with a potential clinical application

An abstract of the study is available online at http://www.ors.org/web/Media.asp.

For more information about the Orthopaedic Research Society, visit the ORS Web site (http://www.ors.org/web/about_the_ors/welcome.asp).


'/>"/>
SOURCE Orthopaedic Research Society
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
2. Breast Cancer Clinical Results Show Test Can Differentiate Normal, Early and Later Stage Cancers
3. Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
4. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
5. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
6. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
7. New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
8. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
9. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
10. New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
11. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
Breaking Medicine News(10 mins):